LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma

Memorial Sloan Kettering Cancer Center17 enrolled

Overview

Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts: * Induction ends on day 19 * Consolidation ends on day 38 or 42 * Maintenance may include up to 6 cycles

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Non-Hodgkin's Lymphoma

Interventions

LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNUDRUG

LSA4 intervention includes three phases: induction, consolidation and maintenance

Eligibility

Sex: ALLMax age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Non-Hodgkin's Lymphoma stages III, IV, IVA with 1. T cell lymphomas, any primary site irrespective of LDH level 2. large cell lymphomas, any primary site irrespective of LDH level 3. B cell lymphomas, any primary site with initial LDH of less than 500 Exclusion Criteria: * B cell lymphomas, any primary site with initial LDH of less than 500 and initial CNS or bone involvement

Locations (1)

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Outcomes

Primary Outcomes

Complete Remission

The number of patients who achieved a complete remission as a result of treatment

Time frame: 330 Days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.